LCM
MCID: MNT001
MIFTS: 69

Mantle Cell Lymphoma (LCM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Mantle Cell Lymphoma

MalaCards integrated aliases for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 12 75 53 59 37 29 6 15 38 17 33
Lcm 59 3
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 72
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 72
Lymphoma, Mantle Cell 53
Lymphoma, Mantle-Cell 44
Mantle Zone Lymphoma 59
Lymphoma Mantle-Cell 55
Mcl 59

Characteristics:

Orphanet epidemiological data:

59
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050746
KEGG 37 H01464
MeSH 44 D020522
ICD10 33 C83.1
MESH via Orphanet 45 D020522
ICD10 via Orphanet 34 C83.1
UMLS via Orphanet 73 C0555202
Orphanet 59 ORPHA52416
UMLS 72 C0334634 C0555202

Summaries for Mantle Cell Lymphoma

CDC : 3 Lymphocytic choriomeningitis, or LCM, is a rodent-borne viral infectious disease caused by lymphocytic choriomeningitis virus (LCMV), a member of the family Arenaviridae, that was initially isolated in 1933. The primary host of LCMV is the common house mouse, Mus musculus. Infection in house mouse populations may vary by geographic location, though it is estimated that 5% of house mice throughout the United States carry LCMV and are able to transmit virus for the duration of their lives without showing any sign of illness. Other types of rodents, such as hamsters, are not the natural reservoirs but can become infected with LCMV from wild mice at the breeder, in the pet store, or home environment. Humans are more likely to contract LCMV from house mice, but infections from pet rodents have also been reported.

MalaCards based summary : Mantle Cell Lymphoma, also known as lcm, is related to follicular lymphoma and lymphoma, hodgkin, classic. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are Human cytomegalovirus infection and PI3K-Akt signaling pathway. The drugs Orange and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are lymphadenopathy and b-cell lymphoma

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

NIH Rare Diseases : 53 Mantle cell lymphoma (MCL) belongs to a group of diseases known as non-Hodgkin's lymphomas (NHL). NHL's are cancers that affect the the lymphatic system (part of the immune system). In MCL, there are cancerous B-cells (a type of immune system cell). The cancerous B-cells are within a region of the lymph node known as the mantle zone. Although MCLs are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. In these situations, treatment must be intensive since MCL can become life threatening within a short period of time. MCL accounts for 6% of all NHL's and is mostly found in males during their early 60s.

KEGG : 37
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma (NHL) and it accounts for about 6% of all NHL cases. Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. The molecular hallmark and putative initiating oncogenic event in MCL is the t(11;14)(q13;q32) translocation resulting in constitutional overexpression of cyclin D1 and cell cycle dysregulation in almost all cases. Clinically, MCL shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. However, recently a subset of 15% long-term survivors has been identified with a rather indolent clinical course.

Wikipedia : 75 Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 427)
# Related Disease Score Top Affiliating Genes
1 follicular lymphoma 33.6 MYC MME MCL1 CCND1 BCL6 BCL2
2 lymphoma, hodgkin, classic 32.7 MME CD5 BCL6
3 lymphoma 32.3 MYC GAS5 EZH2 CCND1 BCL6 BCL2
4 marginal zone b-cell lymphoma 32.1 MME CD5 CCND1 BCL6 BCL2
5 composite lymphoma 32.0 SOX11 CD5 BCL6
6 lymphocytic leukemia 31.9 TP53 MYC MME MCL1 CD5 BTK
7 leukemia, chronic lymphocytic 31.9 TP53 MCL1 IGH CD5 CCND2 CCND1
8 prolymphocytic leukemia 31.8 MYC CD5 CCND1 ATM
9 diffuse large b-cell lymphoma 31.7 TP53 MYC MME MDM2 EZH2 CD5
10 cll/sll 31.7 TP53 SOX11 MME CD5 CCND1 ATM
11 autoimmune lymphoproliferative syndrome, type v 31.7 CD5 BCL6 BCL2
12 richter's syndrome 31.7 TP53 MYC CD5 ATM
13 b cell prolymphocytic leukemia 31.6 TP53 MYC CD5
14 lymphoma, non-hodgkin, familial 31.6 TP53 MYC MME MDM2 MCL1 IGH
15 mature b-cell neoplasm 31.5 TP53 MYC MME BCL6
16 lymphoma, mucosa-associated lymphoid type 31.5 MME IGH CD5 CCND1 BCL6 BCL2
17 adenocarcinoma 31.5 TP53 MYC MALAT1 CCND1
18 burkitt lymphoma 31.5 SOX11 MYC MME MCL1 CCND2 BCL6
19 retinoblastoma 31.4 TP53 MDM2 MALAT1 CCND1
20 nodal marginal zone b-cell lymphoma 31.4 BCL6 BCL2
21 lymphoblastic lymphoma 31.2 MME CD5 BCL6
22 peripheral t-cell lymphoma 31.2 MME CD5 BCL6
23 leukemia, acute lymphoblastic 3 31.2 TP53 MME IGH
24 leukemia, acute myeloid 31.1 TP53 MYC MME MCL1 MALAT1 EZH2
25 acquired immunodeficiency syndrome 30.9 TP53 MYC BCL6
26 breast lymphoma 30.9 CD5 BCL6
27 t-cell leukemia 30.9 TP53 MYC GAS5 CCND2 ATM
28 myeloma, multiple 30.7 TP53 MYC MME MCL1 MALAT1 GAS5
29 hematologic cancer 30.5 TP53 MYC MME MCL1 CD5 BMI1
30 testicular lymphoma 30.3 MME BCL6
31 squamous cell carcinoma, head and neck 30.2 TP53 MYC GAS5 CCND1
32 nasopharyngeal carcinoma 29.8 TP53 MYC MDM2 MALAT1 GAS5 CCND1
33 bladder cancer 29.8 TP53 MYC MDM2 MALAT1 GAS5 EZH2
34 kidney cancer 29.8 TP53 MALAT1 GAS5
35 ovarian cancer 29.7 TP53 MYC MDM2 MALAT1 GAS5 CCND1
36 breast cancer 29.6 TP53 MYC MDM2 MALAT1 GAS5 EZH2
37 prostate cancer 29.2 TP53 MYC MIR16-1 MDM2 MCL1 MALAT1
38 hairy cell leukemia 11.8
39 b-cell lymphoma 11.0
40 diffuse large b-cell lymphoma of the central nervous system 11.0 MYC BCL2
41 leukemia, b-cell, chronic 11.0
42 synchronous bilateral breast carcinoma 10.9 TP53 CCND1 ATM
43 zika virus infection 10.9 TP53 MDM2
44 ring chromosome 7 10.9 TP53 MDM2
45 suppressor of tumorigenicity 3 10.9 TP53 MYC BCL2
46 hidradenocarcinoma 10.9 TP53 CCND1 BCL2
47 keratocystic odontogenic tumor 10.9 TP53 CCND1 BCL2
48 myxosarcoma 10.9 TP53 MDM2 ATM
49 soft tissue sarcoma 10.9 TP53 MDM2 BCL2
50 verrucous carcinoma 10.9 TP53 MDM2 CCND1

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

59 32 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
2 b-cell lymphoma 59 32 hallmark (90%) Very frequent (99-80%) HP:0012191
3 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
4 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
5 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
6 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
7 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
8 abnormality of bone marrow cell morphology 59 32 frequent (33%) Frequent (79-30%) HP:0005561
9 abnormality of the gastrointestinal tract 59 32 occasional (7.5%) Occasional (29-5%) HP:0011024

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.63 BCL6 BMI1 CCND2 MDM2 MYC TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 BMI1 MCL1 MDM2 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 ATM BCL2 MCL1 TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ATM BCL2 BTK CCND1 MCL1 MYC

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.24 ATM BCL2 BCL6 BTK CCND1 EZH2
2 hematopoietic system MP:0005397 10.22 ATM BCL2 BCL6 BTK CCND1 CCND2
3 cardiovascular system MP:0005385 10.21 ATM BCL2 BCL6 CCND1 CCND2 EZH2
4 endocrine/exocrine gland MP:0005379 10.17 ATM BCL2 BCL6 CCND1 CCND2 EZH2
5 immune system MP:0005387 10.17 ATM BCL2 BCL6 BTK CCND1 CCND2
6 homeostasis/metabolism MP:0005376 10.15 ATM BCL2 BCL6 BTK CCND1 CCND2
7 embryo MP:0005380 10.06 ATM BCL2 EZH2 MCL1 MDM2 MYC
8 integument MP:0010771 10.03 ATM BCL2 BTK CCND1 CD5 EZH2
9 digestive/alimentary MP:0005381 10.02 BCL2 BTK CCND1 MDM2 MYC SOX11
10 neoplasm MP:0002006 9.76 ATM BCL2 BTK CCND1 EZH2 MDM2
11 normal MP:0002873 9.61 BCL6 CCND1 CD5 EZH2 MCL1 MDM2
12 reproductive system MP:0005389 9.28 ATM BCL2 BCL6 CCND1 CCND2 MCL1

Drugs & Therapeutics for Mantle Cell Lymphoma

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 439)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Orange Approved Phase 3
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
4
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
5
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
6
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
7
Ribavirin Approved Phase 3 36791-04-5 37542
8
Chlorambucil Approved Phase 3 305-03-3 2708
9
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
10
Ondansetron Approved Phase 3 99614-02-5 4595
11
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
12
Dalteparin Approved Phase 3 9005-49-6
13
Ofloxacin Approved Phase 3 82419-36-1 4583
14
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
15
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
18
Tazobactam Approved Phase 3 89786-04-9 123630
19
Piperacillin Approved Phase 3 66258-76-2 43672
20
Vancomycin Approved Phase 3 1404-90-6 441141 14969
21
Palivizumab Approved, Investigational Phase 3 188039-54-5
22
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
23
Captopril Approved Phase 3 62571-86-2 44093
24
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
25
Acyclovir Approved Phase 3 59277-89-3 2022
26
Morphine Approved, Investigational Phase 3 57-27-2 5288826
27
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
28
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
29
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
30
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
31
tannic acid Approved Phase 3 1401-55-4
32
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
33
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
leucovorin Approved Phase 3 58-05-9 143 6006
36
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
37
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
38
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
39
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
40
Polyestradiol phosphate Approved Phase 3 28014-46-2
41
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
42
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
43
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
44 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
45 Interferon-alpha Phase 3
46 Interferon alpha-2 Phase 3
47 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
48 beta-Lactamase Inhibitors Phase 3
49 Amoxicillin-Potassium Clavulanate Combination Phase 3
50 Anesthetics, Dissociative Phase 3

Interventional clinical trials:

(show top 50) (show all 1020)
# Name Status NCT ID Phase Drugs
1 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
2 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial Recruiting NCT02858804 Phase 4 Etoposide;Doxorubicin;Dexamethasone;Vincristine;Cyclophosphamide;Cytarabine;Cisplatin;Rituximab;Thalidomide;Prednisone
4 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
5 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
6 Efficacy and Safety of Rituximab, High-dose Ara-C and Dexamethasone (R-HAD) Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Unknown status NCT01449344 Phase 3 Rituximab;High dose Ara-C;Dexamethasone;Bortezomib
7 Efficacy of Maintenance Therapy With Rituximab After Induction Chemotherapy (R-CHOP vs. R-FC) for Elderly Patients With Mantle Cell Lymphoma Not Suitable for Autologous Stem Cell Transplantation Unknown status NCT00209209 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Fludarabine;Interferon-alpha;pegylated formula Interferon-alpha 2b
8 Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation Unknown status NCT00209222 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Cisplatinum;Ara-C;Dexamethasone;BCNU;Melphalan;Etoposide;G-CSF
9 Treatment of Mantle Cell Lymphomas at Advanced Stages: Prospective Randomized Comparison of Myeloablative Radiochemotherapy Followed by Blood Stem Cell Transplantation Versus Maintenance With Interferon Alpha in First Remission After Initial Cytoreductive Chemotherapy With an Anthracycline Containing Combination Unknown status NCT00016887 Phase 3 carmustine;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan
10 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
12 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Randomised Trial Comparing Chemotherapy Mit CHOEP (Cyclophosphamid, Doxorubicin, Vincristin, Etoposid Und Prednison) In 21-Day Intervals In Standard And Escalated Doses In Patients Aged 18-60 Years Of Age With Aggresive Non-Hodgkin-Lymphomas Favourable Prognoses Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
14 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
16 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
17 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
18 Manteau 2007 SJ "LYMA" "Randomized, Open-label, Phase III Study Efficacy of Rituximab Maintenance Therapy in Patients 18 to 65 Years , First-line Treatment for MCL Completed NCT00921414 Phase 3 Rituximab
19 An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT00877006 Phase 3 bendamustine;rituximab;vincristine;prednisone;cyclophosphamide;doxorubicin
20 Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma Completed NCT00641095 Phase 2, Phase 3 Cyclophosphamide;Fludarabine
21 A Randomized, Phase III Trial to Determine the Effect of Consolidation With Rituximab (IDEC C2B8-Mabthera) in Patients With CD20+ Follicular or Mantle Cell Lymphoma Having Received Induction Therapy With Rituximab Weekly x 4 Completed NCT00003280 Phase 3
22 A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3 Ibrutinib;Temsirolimus
23 An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3 Temsirolimus (CCI-779);Temsirolimus (CCI-779);Investigator's choice
24 A Randomized, Open-Label, Multicenter Phase 3 Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone (VcR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Patients With Newly Diagnosed Mantle Cell Lymphoma Who Are Not Eligible for a Bone Marrow Transplant Completed NCT00722137 Phase 3 Rituximab 375 mg/m^2;Cyclophosphamide 750 mg/m^2;Doxorubicin 50 mg/m^2;VELCADE 1.3 mg/m^2;Prednisone 100 mg/m^2;Vincristine 1.4 mg/m^2
25 A Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3 Bendamustine;Rituximab
26 Prospective Randomised Multicenter Study for Therapy Optimization of Recurrent, Progressive Low Grade Non-Hodgkin Lymphomas and Mantle Cell Lymphomas Completed NCT01456351 Phase 3 Bendamustine plus Rituximab;Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w
27 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
28 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
29 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
30 A Randomized, Open-label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma Completed NCT00269113 Phase 3 rituximab [MabThera/Rituxan];Standard chemotherapy
31 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
32 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
33 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
34 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
35 Randomized Study Comparing 4 and 6 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 21-day Intervals, Both With 6 Cycles of Immunotherapy With the Monoclonal Anti-CD20-Positive B-Cell Lymphoma Aged 18-60 Years Having no Risk Factor (Age-Adjusted IPI=0) and No Large Tumor Mass (Diameter <7,5cm) [FLYER 6-6-6-4 Study] Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
37 A Phase III Randomized Trial of CHOP Chemotherapy Plus Rituxan (IDEC-C2B8) Versus CHOP Chemotherapy Alone for Newly Diagnosed, Previously Untreated, Aggressive Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
38 A Double-Blind Study Of Nutritional Intervention For The Treatment Of Cancer Cachexia Using Juven® Nutritional Supplement Completed NCT00053053 Phase 3
39 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
40 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
41 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
42 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
43 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
44 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
45 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
46 Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study] Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
48 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
49 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
50 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B

Search NIH Clinical Center for Mantle Cell Lymphoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acalabrutinib
Bortezomib
Ibrutinib
Ibrutinib
Lenalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

# Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Lymph Node, Myeloid, Colon

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 4418)
# Title Authors PMID Year
1
Mantle cell lymphoma is characterized by inactivation of the ATM gene. 38 71
10706620 2000
2
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. 38 88
18483394 2008
3
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 9 38
20062012 2010
4
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. 9 38
18606985 2008
5
Increased MDM2 expression is associated with inferior survival in mantle-cell lymphoma, but not related to the MDM2 SNP309. 9 38
17488676 2007
6
[Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor]. 9 38
17145584 2006
7
Peripheral blood complete remission after splenic irradiation in mantle-cell lymphoma with 11q22-23 deletion and ATM inactivation. 9 38
16956411 2006
8
Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. 9 38
16448697 2006
9
Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. 9 38
11389032 2001
10
Differential expression of cyclin D1 in mantle cell lymphoma and other non-Hodgkin's lymphomas. 9 38
9846986 1998
11
Analysis of the cyclin-dependent kinase inhibitors p18 and p19 in mantle-cell lymphoma and chronic lymphocytic leukemia. 9 38
9209645 1997
12
Chronic lymphoproliferative disorders. 9 38
9090492 1997
13
Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. 9 38
8695815 1996
14
Mantle-cell lymphoma: classification and therapeutic implications. 9 38
9010577 1996
15
Over-expression of cyclin D1 in chronic B-cell malignancies with abnormality of chromosome 11q13. 9 38
7772515 1995
16
Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. 9 38
8204893 1994
17
PRAD1 gene over-expression in mantle-cell lymphoma but not in other low-grade B-cell lymphomas, including extranodal lymphoma. 9 38
7918073 1994
18
Identification of genetic lesions associated with diffuse large-cell lymphoma. 9 38
8172819 1994
19
Sinus-confined involvement pattern of mantle cell lymphoma. 38
31289998 2019
20
Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. 38
31233483 2019
21
Overexpression of lncRNA GATA6-AS inhibits cancer cell proliferation in mantle cell lymphoma by downregulating GLUT1. 38
31402946 2019
22
miR‑29 promotes the proliferation of cultured rat neural stem/progenitor cells via the PTEN/AKT signaling pathway. 38
31257508 2019
23
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 38
30045683 2019
24
Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma. 38
31229421 2019
25
Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma. 38
31366503 2019
26
Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions. 38
31229158 2019
27
Pro-apoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. 38
31425695 2019
28
An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process. 38
31433838 2019
29
Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma. 38
31408711 2019
30
Feature article: Development of a clinically relevant chemoresistant mantle cell lymphoma cell culture model. 38
31208205 2019
31
CD5-negative Mantle Cell Lymphoma: Clinicopathologic Correlations and Outcome in 58 Patients. 38
31045891 2019
32
Clinical management of mantle cell lymphoma in the elderly. 38
31373238 2019
33
Mantle cell lymphoma with lymphocyte aggregates in peripheral blood. 38
31124577 2019
34
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. 38
31371411 2019
35
Diagnostic and Clinical Impact of Staging 18F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. 38
31129112 2019
36
Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL. 38
31031018 2019
37
Drugging OXPHOS Dependency in Cancer. 38
31186236 2019
38
Rare presentation of ileocolic intussusception secondary to mantle cell lymphoma. 38
31420425 2019
39
Analysis of 153,115 patients with hematological malignancies refines the spectrum of familial risk. 38
31395603 2019
40
IL-10-producing B cells are characterized by a specific methylation signature. 38
31034584 2019
41
Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma. 38
31395597 2019
42
Mantle Cell Lymphoma: Which Patients Should We Transplant? 38
31218478 2019
43
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. 38
30696305 2019
44
ALK-positive anaplastic large cell lymphoma presenting multiple lymphomatous polyposis: A case report and literature review. 38
31423437 2019
45
Mantle Cell Lymphoma With Mantle Zone Growth Pattern. 38
31140550 2019
46
Optimal management of mantle cell lymphoma in the primary setting. 38
31268728 2019
47
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. 38
31286200 2019
48
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. 38
30929200 2019
49
Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts? 38
31348229 2019
50
RIP sequencing in mantle cell lymphoma identifies functional long non-coding RNAs associated with translation machinery. 38
31350385 2019

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 11:108199926-108199926 11:108329199-108329199
2 ATM NM_000051.3(ATM): c.7251_7253dup (p.Lys2418dup) duplication Pathogenic rs796051857 11:108199909-108199911 11:108329182-108329184
3 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 11:108158414-108158414 11:108287687-108287687

Cosmic variations for Mantle Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1644297 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.17T>C p.L6P 11:69641330-69641330 0

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.99 TP53 MYC MDM2 CCND1 BCL2 ATM
2
Show member pathways
12.98 TP53 MYC MDM2 MCL1 CCND2 CCND1
3
Show member pathways
12.88 TP53 MYC MDM2 CCND1 BCL2
4 12.88 TP53 MYC MDM2 CCND2 CCND1 BCL2
5
Show member pathways
12.85 TP53 MYC MDM2 MCL1 BCL2 ATM
6
Show member pathways
12.74 TP53 MYC MDM2 CCND1 BCL2 ATM
7
Show member pathways
12.73 TP53 MDM2 CCND2 CCND1 BCL2 ATM
8
Show member pathways
12.6 TP53 MYC MDM2 CCND1
9
Show member pathways
12.59 TP53 MYC MDM2 CCND2 CCND1 ATM
10 12.55 TP53 MDM2 CCND2 CCND1 ATM
11
Show member pathways
12.49 MYC CCND2 CCND1 BCL2
12
Show member pathways
12.45 TP53 MDM2 BCL2 ATM
13
Show member pathways
12.45 MYC MCL1 CCND2 CCND1 BCL2
14 12.43 TP53 MYC CCND2 CCND1
15 12.4 TP53 MYC CCND2 CCND1 ATM
16
Show member pathways
12.4 TP53 MYC MDM2 IGH CCND2 CCND1
17
Show member pathways
12.37 TP53 CCND2 CCND1 ATM
18 12.36 TP53 MYC MDM2 CCND2 CCND1 ATM
19 12.32 TP53 MDM2 CCND2 CCND1
20 12.32 TP53 MYC MDM2 CCND1
21
Show member pathways
12.27 TP53 MDM2 CCND1 BCL2 ATM
22
Show member pathways
12.23 TP53 MYC MIR16-1 MDM2 CCND2 CCND1
23
Show member pathways
12.22 TP53 MYC MDM2 CCND2 CCND1 BCL2
24 12.21 TP53 MYC CCND2 CCND1
25 12.18 TP53 MYC MDM2 CCND2 CCND1 ATM
26 12.18 TP53 MYC MDM2 CCND2 BMI1 BCL6
27 12.16 TP53 MYC MDM2 CCND1 BCL2
28 12.14 TP53 MYC MDM2 CCND1 BCL2 ATM
29
Show member pathways
12.12 MYC CCND2 BTK BCL2
30
Show member pathways
12.11 MDM2 CCND2 CCND1 BCL6 ATM
31 12.09 TP53 MDM2 MCL1 BCL6 BCL2
32 12.08 TP53 MDM2 BCL2 ATM
33 12.05 TP53 MYC MDM2 CCND1
34 12.01 TP53 MYC MDM2 CCND1
35 11.99 TP53 MDM2 BMI1 BCL2
36 11.94 TP53 MYC MCL1 CCND1 BCL6 BCL2
37 11.92 BTK BCL2 ATM
38 11.91 TP53 MYC CCND1 BCL2
39
Show member pathways
11.9 MYC BTK BCL2
40 11.87 TP53 MYC MDM2 CCND1
41
Show member pathways
11.85 TP53 MDM2 ATM
42 11.85 TP53 MYC MIR16-1 MDM2 MCL1 EZH2
43 11.83 TP53 MYC CCND2 BMI1
44 11.8 MYC CCND2 CCND1
45 11.8 MYC CCND1 BCL2
46 11.78 TP53 MDM2 BCL2 ATM
47 11.78 TP53 MYC MDM2 CCND1
48
Show member pathways
11.76 TP53 MDM2 ATM
49 11.76 MYC MCL1 ATM
50 11.73 TP53 MDM2 BCL2 ATM

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 TP53 MYC MDM2 MCL1 EZH2 CCND2

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 TP53 SOX11 MYC CD5 BCL2
2 cellular response to DNA damage stimulus GO:0006974 9.95 TP53 MYC CCND1 BCL6 BCL2 ATM
3 negative regulation of apoptotic process GO:0043066 9.95 TP53 MYC MDM2 MCL1 CCND2 BCL6
4 negative regulation of gene expression GO:0010629 9.94 SOX11 MYC MDM2 EZH2
5 regulation of apoptotic process GO:0042981 9.91 TP53 MCL1 BCL6 BCL2 ATM
6 positive regulation of cell proliferation GO:0008284 9.87 SOX11 MYC MDM2 EZH2 CCND2 CCND1
7 regulation of gene expression GO:0010468 9.85 MYC MDM2 EZH2 BMI1 BCL2
8 regulation of signal transduction by p53 class mediator GO:1901796 9.8 TP53 MDM2 ATM
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.79 TP53 MDM2 ATM
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.77 MIR16-1 EZH2 BCL2
11 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.76 MCL1 BCL2 ATM
12 negative regulation of transcription by RNA polymerase II GO:0000122 9.76 TP53 SOX11 MYC MDM2 EZH2 CCND1
13 cellular response to organic substance GO:0071310 9.75 MDM2 CCND1 BCL2
14 liver regeneration GO:0097421 9.74 MYC EZH2 CCND1
15 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.73 TP53 MIR16-1 BCL2
16 response to steroid hormone GO:0048545 9.71 MDM2 CCND1 BCL2
17 response to gamma radiation GO:0010332 9.7 TP53 MYC BCL2
18 cellular response to gamma radiation GO:0071480 9.67 TP53 MDM2 ATM
19 cellular response to estrogen stimulus GO:0071391 9.65 MYC MDM2
20 response to magnesium ion GO:0032026 9.65 MDM2 CCND1
21 positive regulation of response to DNA damage stimulus GO:2001022 9.64 MYC ATM
22 regulation of mitochondrial membrane permeability GO:0046902 9.63 TP53 BCL2
23 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
24 re-entry into mitotic cell cycle GO:0000320 9.61 MYC CCND1
25 response to iron ion